Market research
MDXH.BR MDxHealth SA
BR EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 86M
- P/E ratio
- Not available
- Analyst target
- 6.98
- Dividend yield
- Not available
- Beta
- 0.79
Profile
Company facts
- Exchange
- BR
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- BE0003844611
- Market cap
- 86M
- P/E ratio
- Not available
- Analyst target
- 6.98
- Dividend yield
- Not available
- Beta
- 0.79
About
About MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MDXH.BR discussion.
5 years, 6 months ago
MDxHealth SA is currently in a long term uptrend where the price is trading 27.2% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.8.
Its net income has increased by 52.7% to $-14M since the same quarter in the previous year.
Finally, its free cash flow fell by 7.4% to $-5M since the same quarter in the previous year.
Based on the above factors, MDxHealth SA gets an overall score of 3/5.